Creative Medical Technology Holdings vs Virax Biolabs Group
Virax Biolabs Group is the larger business, with $12,423 of revenue in fiscal 2026 against $6,000 for Creative Medical Technology Holdings (2.1 times as much). Virax Biolabs Group grew faster (96.2% against -45.5%). Virax Biolabs Group kept more of each dollar of sales as profit: a net margin of -40439.1% against -99916.8%. Creative Medical Technology Holdings carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Creative Medical Technology HoldingsCELZ, 2025 | Virax Biolabs GroupVRAX, 2026 |
|---|---|---|
| Revenue | $6,000 | $12,423 |
| Revenue growth | -45.5% | 96.2% |
| Net income | −$6.0m | −$5.0m |
| Operating margin | -102380.2% | -51515.2% |
| Net margin | -99916.8% | -40439.1% |
| Return on equity | -86.5% | -75.7% |
| Free cash flow | — | −$4.9m |
| Cash | $7.2m | $6.4m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $10,000 | — |
| Employees | — | — |
| Market value | $4.3m | $613,971 |
| Price vs our value range | — | — |
| Moat score | 35 (Weak) | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |